PIK3CA Mutational Status Assessment

Recruiting Observational Study
Breast Cancer Metastatic
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Observational
Participants needed
100 (estimated)
Sponsor
European Institute of Oncology · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory. * Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negat…
Contacts

Nicola Fusco, MD

00390294372079

nicola.fusco@ieo.it

CONTACT

francesca lombardi, biologist

00390257489425

francesca.lombardi@ieo.it

CONTACT